Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late ...

Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment ...

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big ...

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 20% in the morning session after investors took profits as the ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Moderna shares fell sharply despite positive melanoma trial results as Jefferies modeled $54 billion in peak sales for its ...

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched ...

The biggest positive for Moderna, Inc. (NASDAQ:MRNA) is that Intismeran could become the product that changes the company’s ...

Moderna’s mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.